Halmos, B., Burke, T., Kalyvas, C., Insinga, R., Vandormael, K., Frederickson, A., & Piperdi, B. (2020). A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC. Cancers (Basel).

Halmos, Balazs, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, and Bilal Piperdi. "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy Vs. Nivolumab + Ipilimumab As First-Line Therapies in Patients With PD-L1 TPS ≥1% Metastatic NSCLC." Cancers (Basel) 2020.

Halmos, Balazs, et al. "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy Vs. Nivolumab + Ipilimumab As First-Line Therapies in Patients With PD-L1 TPS ≥1% Metastatic NSCLC." Cancers (Basel) 2020.